Approved and investigational fluorescent optical imaging agents for disease detection in surgery.
Journal
International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
07
10
2022
accepted:
01
05
2023
medline:
22
8
2023
pubmed:
17
5
2023
entrez:
17
5
2023
Statut:
epublish
Résumé
Fluorescent optical imaging is becoming an increasingly attractive imaging tool that physicians can utilise as it can detect previously 'unseen' changes in tissue at a cellular level that are consistent with disease. This is possible using a range of fluorescently labelled imaging agents that, once excited by specific wavelengths of light, can illuminate damaged and diseased tissues. For surgeons, such agents can permit dynamic, intraoperative imaging providing a real-time guide as they resect diseased tissue.
Identifiants
pubmed: 37195806
doi: 10.1097/JS9.0000000000000459
pii: 01279778-202308000-00024
pmc: PMC10442106
doi:
Substances chimiques
Fluorescent Dyes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2378-2387Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
National Institute of Biomedical Imaging and Engineering. Optical Imaging. Accessed March 2022 https://www.nibib.nih.gov/science-education/science-topics/optical-imaging
Leitgeb RA, Baumann B. Multimodal optical medical imaging concepts based on optical coherence tomography. Front in Phys 2018;6:114.
Croce AC, Bottiroli G. Autofluorescence spectroscopy and imaging: a tool for biomedical research and diagnosis. Eur J Histochem 2014;58:4.
Saito K, Fujiwara T, Ota U, et al. Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochem Biophys Rep 2017;13:105–111.
Brody T. Inorganic nutrients. Nutritional Biochemistry (Second Edition) Academic Press 1999:693–878.
Bhagavan N, Ha C. Metabolism of Iron and Haem. Essentials of medical biochemistry (Second Edition). Amsterdam: Elsevier Academic Press; 2015:511–529.
Kondo M, Hirota N, Takaoka T, et al. Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat. Cell Biol Toxicol 1993;9:95–105.
Ross JL, Cooper LAD, Kong J, et al. 5-Aminolevulinic acid guided sampling of glioblastoma microenvironments identifies pro-survival signalling at infiltrative margins. Sci Rep 2017;7:15593.
Hadjipanayis CG, Stummer W, Sheehan JP. 5-ALA fluorescence-guided surgery of CNS tumours. J Neurooncol 2019;141:477–478.
Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas. Neurosurgery 2015;77:663–673.
Maragkos GA, Schüpper AJ, Lakomkin N, et al. Fluorescence-guided high-grade glioma surgery more than four hours after 5-aminolevulinic acid administration. Front Neurol 2021;12:644804.
Makkawi AK, El Almadieh TY, Wu EM, et al. The Use of 5-Aminolevulinic acid in low-grade glioma resection: a systematic review. Operative Neurosurgery 2019;19:1–8.
National Institute for Health and Care Excellence. Brain Tumours (primary) and Brain Metastases in over 16s. Accessed March 2022. https://www.nice.org.uk/guidance/ng99
Mahmoudi K, Garvey KL, Bouras A, et al. 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J Neurooncol 2019;141:595–607.
Inoue K. 5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer. Int J Urol 2017;24:97–101.
Ishizuka I, Abe F, Sano Y, et al. Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol 2011;11:358–365.
Whelan H. Photodynamic Therapy for Benign Dermal Neurofibromas – Phase II. ClinicalTrials.gov. Identifier: NCT02728388. Updated January 4, 2023. Accessed April 2022. https://clinicaltrials.gov/ct2/show/NCT02728388
Bottaro D, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802–804.
Cheng F, Guo D. MET in glioma: signalling pathways and targeted therapies. J Exp Clin Cancer Res 2019;38:270.
Organ SL, Tsao MS. An overview of the c-MET signalling pathway. Ther Adv Med Oncol 2011;3:S7–S19.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172–187.
Sierra JF, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011;3:S21–S35.
Dransfield DT, Ladner RC, Nanjappan P, et al., inventors: Takada Pharmaceutical Co Ltd, assignee. Peptides that specifically bind HGF receptor (cMet) and uses thereof. Australian patent: AU2010235865B2. November 15, 2012.
Burggraaf J, Kamerling IM, Gordon PB, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med 2015;21:955–961.
Colucci P, Yale SH, Rall CJ, et al. Colorectal Polyps. Clin Med Res 2003;1:261–262.
Jayne D. EMI-137 in Laparoscopic Colonic Resections. ClinicalTrials.gov. Identifier: NCT03360461. Updated October 15, 2018. Accessed April 2022. https://clinicaltrials.gov/ct2/show/NCT03360461
De Jongh SJ, Voskuil F, Schmidt I, et al. C-Met targeted fluorescence molecular endoscopy in Barrett’s esophagus patients and identification of outcome parameters for phase-I studies. Theranostics 2020;10:5357–5367.
Low PS, Kularatne SA, Kelderhouse LE, inventors: Purdue Research Foundation, assignee. Methods of Imaging Inflammatory Diseases by Ligands Conjugated to Fluorescent Compounds. US patent: US20140271484A1. January 12, 2016.
Mahalingam S, Kularatne SA, Myers CH, et al. Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer. J Med Chem 2018;61:9637–9646.
Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumour target in epithelial ovarian cancer. Gynecol Oncol 2008, 108 3:619–626.
O’Shannessy DJ, Somers EB, Maltzman J, et al. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus 2012;28 1:22.
Ross JF, Chaudhuri PK, Ratnam R. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 1994;73:2432–2443.
Cheung A, Bax HJ, Josephs DH, et al. 2016 Targeting folate receptor alpha for cancer treatment. Oncotarget, 2016 7:32 52553–52574.
Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol 2020;17:349–359.
DiSaia P, Creasman W, Mannell R, et al. Targeted therapy and molecular genetics. Clinical Gynaecologic Oncology (Ninth Edition). Elsevier; 2018.
On Target Laboratories. OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer. ClinicalTrials.gov. Identifier: NCT03180307. Updated February 4, 2022. Accessed April 2022. https://clinicaltrials.gov/ct2/show/NCT03180307
On Target Laboratories. ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting (Elucidate). ClinicalTrials.gov. Identifier: NCT04241315. Updated March 23, 2023. https://clinicaltrials.gov/ct2/show/NCT04241315
Food and Drug Administration. Approved Drugs: FDA approves pafolacianine for identifying malignant ovarian cancer lesions. Accessed April 2022. https://www.fda.gov/drugs
Predina JD, Newton A, Xia L, et al. An open label trial of folate receptor-targeted intraoperative molecular imaging to localize pulmonary squamous cell carcinomas. Oncotarget 2018;9:13517–13529.
Veiseh M, Gabikian P, Bahrami SB, et al. Tumour paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007;67:6882–6888.
Patil CG, Walker DG, Miller DM, et al. Phase 1 safety, pharmacokinetics, and fluorescence imaging study of tozuleristide (BLZ-100) in adults with newly diagnosed or recurrent gliomas. Neurosurgery 2019;85:E641–E649.
Blaze Bioscience Inc. Study of Tozuleristide and the Canvas Imaging System in Paediatric Subjects With CNS Tumours Undergoing Surgery. ClinicalTrials.gov. Identifier: NCT03579602. Updated November 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03579602
Soroceanu L, Gillespie Y, Khazaeli MB, et al. Use of chlorotoxin for targeting of primary brain tumours. Cancer Res 1998;58:4871–4879.
Ojeda PG, Wang CK, Crail DJ. Chlorotoxin: structure, activity, and potential uses in cancer therapy. Biopolymers 2016;106:25–36.
Peretti M, Angelini M, Savalli N, et al. Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumour development and as novel therapeutic targets. Biochim Biophys Acta 2015;1848:2523–2531.
Kittle DS, Mamelak A, Parrish-Novak JE, et al. Fluorescence-guided tumour visualization using the tumor paint BLZ-100. Cureus 2014;6:e210.
Kim K, Cai J, Shuja S, et al. Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas. Int J Cancer 1998;79:324–333.
Rudzińska M, Parodi A, Soond SM, et al. The role of cysteine cathepsins in cancer progression and drug resistance. Int J Mol Sci 2019;20:3602.
Lumicell. Technology Overview . Accessed April 2022 www.lumicell.com
Whitley MJ, Cardona DM, Lazarides AL, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med 2016;8:320.
Lee DW, Bawendi MG, Ferrer J, inventors: Lumicell Inc, assignee Imaging Agent for Detection Of Diseased Cells. US patent: US9763577B2. September 19, 2017.
Whitley M. Preclinical and Clinical Studies of an Investigational Protease-Activated Fluorescent Probe for Cancer Theranostics. [Thesis]. Duke University; 2017.
Lumicell Inc. Investigation of Novel Surgical Imaging for Tumour Excision (INSITE). ClinicalTrials.gov. Identifier NCT03686215. Updated December 16, 2022. https://clinicaltrials.gov/ct2/show/NCT03686215
Fox IJ, Brooker LG, Heseltine DW, et al. A tricarbocyanine dye for continuous recording of dilution curves in whole blood independent of variations in blood oxygen saturation. Proc Mayo Clinic 1957;32:478–484.
Wheeler HO, Cranston WI, Meltzer JI. Hepatic uptake and biliary excretion of indocyanine green in the dog. Proc Soc of Exp Biol Med 1958;99:11–14.
Norat P, Soldozy S, Elsarrag M, et al. Application of indocyanine green videoangiography in aneurysm surgery: evidence, techniques, practical tips. Front Surg 2019;6:34.
Detter C, Wipper S, Russ D, et al. Fluorescent cardiac imaging: a novel intraoperative method for quantitative assessment of myocardial perfusion during graded coronary artery stenosis. Circulation 2007;116:1007–1014.
Boni L, Daivd G, Mangano A, et al. Clinical applications of indocyanine green (ICG) enhanced fluorescence in laparoscopic surgery. Surg Endosc 2015;29:2046–2055.
Alander JT, Kaartinen I, Laakso A, et al. A review of indocyanine green fluorescent imaging in surgery. Int J of Biomed Imaging 2012:940585.
Ergin A, Wang M, Zhang JY, et al. The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green. J of Neurooncol 2012;106:551–560.
Hu Z, Fang C, Li B, et al. First-in-human liver-tumour surgery guided by multispectral fluorescence imaging in the visible and near-infrared-I/II windows. Nat Biomed Eng 2020;4:259–271.
Shi X, Zhang Z, Zhang Z, et al. Near-infrared window ii fluorescence image-guided surgery of high-grade gliomas prolongs the progression-free survival of patients. IEEE Transactions on Biomed Eng 2022;69:1889–1900.
Whitney M, Crisp J, Nguyen L, et al. Fluorescent peptides highlight peripheral nerves during surgery in mice. Nat Biotechnol 2011;29:352–356.
Hussain T, Mastrodimos MB, Raju SC, et al. Fluorescently labelled peptide increases identification of degenerated facial nerve branches during surgery and improves functional outcome. PLoS ONE 2015;10:e0119600.
Antoniadis G, Kretschmer T, Pedro MT, et al. Iatrogenic nerve injuries. Dtsch Arztebl Int 2014;111:273–279.
Baibek A, Ucuncu M, Blackburn EA, et al. Lilienkampf A. Wash‐free, peptide‐based fluorogenic probes for microbial imaging. Peptide Sci 2020;113:e24167.